Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Abingdon Health PLC ( (GB:ABDX) ) has issued an announcement.
Abingdon Health plc, an international developer and manufacturer of rapid lateral flow tests and related regulatory and analytical services, has announced the issuance and admission to trading on AIM of 5,208 new ordinary shares following the exercise of employee share options. The move is a routine capital markets event that increases the company’s total shares in issue to 251,077,850, with no treasury shares held, and provides an updated share capital figure for investors and other stakeholders to use when assessing and disclosing their interests under UK regulatory transparency rules.
The most recent analyst rating on (GB:ABDX) stock is a Hold with a £6.50 price target. To see the full list of analyst forecasts on Abingdon Health PLC stock, see the GB:ABDX Stock Forecast page.
Spark’s Take on GB:ABDX Stock
According to Spark, TipRanks’ AI Analyst, GB:ABDX is a Neutral.
Abingdon Health PLC’s overall stock score is primarily influenced by its mixed financial performance, with strong revenue growth overshadowed by profitability and cash flow challenges. The technical analysis indicates a neutral trend, lacking strong momentum. The valuation is unattractive due to a negative P/E ratio and no dividend yield. These factors collectively result in a moderate overall score.
To see Spark’s full report on GB:ABDX stock, click here.
More about Abingdon Health PLC
Abingdon Health plc is a UK-headquartered med-tech contract service provider specialising in the development, manufacture and distribution of rapid lateral flow tests for an international customer base. Through its CDMO expertise, the group supports customers in areas such as infectious disease, clinical and companion diagnostics, animal health and environmental testing, offering services from initial concept through to routine manufacturing. Its subsidiaries, including Compliance Solutions (Life Sciences), IVDeology and Abingdon Analytical, provide regulatory consultancy, quality management, analytical testing and performance evaluation to help in vitro diagnostic and medical device companies secure approvals in key markets including the US, EU and UK, with operations based in York and Doncaster, England, and Madison, Wisconsin, USA.
Average Trading Volume: 120,040
Technical Sentiment Signal: Sell
Current Market Cap: £16.07M
For an in-depth examination of ABDX stock, go to TipRanks’ Overview page.